pSivida Corp Presentations at ARVO 2009

April 25, 2009

pSivida Corp. announced that seven abstracts describing its ophthalmic drug delivery products and technologies have been accepted by ARVO for presentation at the 2009 Annual Meeting.

The presentations will focus both on the development of pSivida’s next generation bioerodible technologies for ophthalmic drug delivery and on clinical results from the company’s Iluvien™ program in diabetic macular edema (DME), as well as ongoing work with the FDA approved device Retisert®.

pSivida has developed the only treatments currently approved by the U.S. Food and Drug Administration (FDA) for sustained back-of-the-eye drug delivery: Vitrasert® and Retisert, both of which are licensed to Bausch & Lomb, and the Iluvien product currently in fully enrolled Phase III clinical trials conducted by the Company’s licensing partner Alimera Sciences. The NDA filing for Iluvien remains on schedule for early 2010.

Read the full release.




Jump down to form below to submit your own comments

Comments are closed.